← SynDRA
BUFEXAMAC
SynDRA canonical compound SYN0003773 — structure-anchored drug synonym record
| Clinical phase | Withdrawn |
| Primary target(s) | HDAC10 | HDAC6 |
| Mechanism of action | cyclooxygenase inhibitor |
All known targets
Mechanisms of action (all sources)
- HDAC10 INHIBITOR
- HDAC6 INHIBITOR
- cyclooxygenase inhibitor
Bioactivity evidence (ChEMBL activities table — not curator-asserted)
- PDE4A
- ACHE
- ADORA3
- IDH1
- KAT2A
- KCNH2
- KDM4E
- KDR
- MAOA
- OPRM1
- PDE3A
- PGR
- PTGS1
- SAMHD1
- SLC6A2
- SLC6A3
- SLC6A4
- SLCO1B1
- SLCO1B3
- SMN1
- SMPD1
- TARDBP
- TBXA2R
- HTR2B
- HTR1A
- HRH3
- CYP2C19
- ADRA1A
- ADRA2A
- ALOX15B
- AR
- ATXN2
- CBX1
- CHRM1
- CHRM2
- CYP1A2
- CYP2C9
- HIF1A
- CYP2D6
- CYP3A4
Screening evidence (raw PubChem HTS — uncurated, known false-positive rate)
- ALR
- AMPL
- ANDR
- CP1A2
- CP2C9
- CP2D6
- HDA10
- IFNG
- KSYK
- MDR1
- NPY1R
- NSD2
- RARA
- SYK
Drug classes
- Analgesics
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Antirheumatic Agents
- Peripheral Nervous System Agents
- Sensory System Agents
ATC classes
- M01A · ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
- M02A · TOPICAL PRODUCTS FOR JOINT AND MUSCULAR PAIN
Cross-references
Synonyms
- bufexamic acid
- feximac
- mofenar
- parfenal
- Bufexamaco
- CP-1044-J3
- NSC-758153
- Duradermal
- Parfenac
- Bufexamic acid
- 2-(4-Butoxyphenyl)-N-hydroxyacetamide
- Parfenal
- Feximac
- Mofenar
- Malipuran
- Droxaryl
- Bufexamacum
- Flogicid
- Paraderm
- Norfemac
- Anderm
- 4-Butoxy-N-hydroxybenzeneacetamide
- p-Butoxyphenylacetohydroxamic acid
- 4-Butoxyphenylacetohydroxamic acid
- Flogocid N plastigel
- Acide p-butoxyphenylacethydroxamique
- 2-(p-Butoxyphenyl)-acetohydroxamic acid
- Bufessamac [DCIT]
- Bufexamacum [INN-Latin]
- Bufexamaco [INN-Spanish]
- CP 1044 J3
- UNII-4T3C38J78L
- Benzeneacetamide, 4-butoxy-N-hyd
- NSC 758153
- CHEBI:31317
- 4T3C38J78L
- DTXCID5025368
- Bufexamacratiopharm
Look up BUFEXAMAC in the interactive SynDRA portal →